Malignant Bowel Obstruction - Definition
Bowel obstructive symptoms due to the presence of an intra-abdominal malignancy.
Often occurs in context of advanced disease.
May be secondary to non-malignant (post-surgical adhesions, radiotherapy bowel damage) or malignant causes (more likely as cancer becomes more advanced, or if primary CA is ovarian)
Most common cancers where malignant bowel obstruction is seen
Cancers metastasizing to the abdomen (esp lung, breast, malignant melanoma).
Pathophysiology of MBO
Mechanical (more common, where the lumen is occluded) or functional (less common)
Mechanical:
Functional (dysmotility)
Contributory causes:
Common symptoms of MBO
Differential diagnosis of MBO
Presentation of MBO
Symptoms:
Common signs of MBO on exam
Inspection
Palpation
Auscultation
Rectal exam
Signs of dehydration
Syndrome of gastric outlet and proximal SBO
Syndrome of distal small bowel MBO
Syndrome of large bowel MBO
Investigation of MBO
Indications for surgery in MBO
Options:
Intraluminal stents for Upper MBO - indications and risks
Risks:
Medical management of MBO
Bowel decompression for MBO
Risks:
Venting gastrostomy or enterostomy
Indicated for patients in whom pharmacological management is not effective, or for very high gastric outlet or upper SBOs that cannot be bypassed
Allows patients to partake in the social experience of eating/drinking
Can do gastrostomy or jejunostomy depending on position of stomach (or if stomach has been removed)
Pharmacologic approach to MBO
Pain relief in MBO
Opioids
PO Loperamide
- May be useful as an antimotility agent, but no clear evidence
Antisecretory agents may also provide pain relief (may give buscopan 40 - 120mg/day) or glycopyrrolate in addition to opioids for colicky pain if opioids alone are ineffective)
Anti-emetics in MBO
Complete relief of N/V due to MBO with anti-emetics alone is usually not possible due to hypermotility and then pooling of secretions and distention of the bowel.
Anti-secretory agents in MBO (rationale, dosing, action, side effects)
Octreotide (somatostatin analogue)
Side effects:
May give buscopan or glycopyrrolate in addition to octreotide
Corticosteroids in MBO (rational, mechanism, dosing)
MOA: likely anti-emetic, analgesic, anti-inflammatory effect that decreases peritumour edema
Dexamethasone 6 - 16mg PO daily
Poor evidence but widely used, does not appear to affect survival
Discontinue if no response within 4-5 days. If there is a response, wean down over time to a minimum effective level
Hydration in MBO
IV or subcut hydration in case of severe fluid imbalance or severe electrolyte abnormalities. Rates should be lower if antisecretory agents are being used and patient is not severely dehydrated
Once secretions, nausea and pain are controlled, most patients can tolerate clear fluids PO until the obstruction resolves
Nutrition - role of TPN or nutritional supplementation
Likely not to improve QOL for patients with survival of less than 3 months
For patients with slow growing tumours involving the GI tract, sparing other major organs, TPN trial in the case of weight loss from starvation may be considered.
For patients who are severely malnourished and in home a surgery is planned but cannot be enterally fed, may be appropriate to consider for 7-10 days preop to decrease rate post op infections, periop mortality, and LOS. Post op duration should be defined preop and generally should be < 10 days.
How to manage patients between episodes of MBO at home
As episodes become more frequent and close together, complete irreversible bowel obstruction is more likely imminent